Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD

Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD

Biogen faces scrutiny following recent Alzheimer's data releases and executive departures. This analysis explores the implications for pharmaceutical business development and investment strategies. With the anti-amyloid class under renewed regulatory and scientific pressure, dealmakers and investors need to reassess how they value Alzheimer's assets — and which companies are positioned to weather the turbulence.

Key Takeaways

• Biogen's mid-stage Alzheimer's data showed an inverted dose-response — the lowest dose produced the strongest cognitive slowing — rattling investor confidence and raising questions about the anti-amyloid mechanism's clinical predictability.
• Chief Medical Officer Maha Makary resigned, stripping Biogen of senior clinical leadership during a critical regulatory and commercial inflection point for its Alzheimer's portfolio.
• Divergent FDA and EMA postures on anti-amyloid antibodies force BD teams to build dual-track regulatory strategies into asset valuations and deal structuring.
• Smaller biotechs with ambiguous Phase II Alzheimer's signals may seek licensing partners at discounted terms, accelerating near-term deal flow for buyers with conviction in the space.

What Did Biogen's Latest Alzheimer's Data Reveal?

Biogen reported mid-stage results for its experimental Alzheimer's drug that complicated the narrative the company — and the broader anti-amyloid field — has been advancing. All dose groups showed slowing of cognitive decline, but the strongest effect emerged in the lowest-dose cohort rather than the highest. This counterintuitive, inverted dose-response finding, first flagged by Endpoints News, immediately triggered skepticism among analysts who expected a clearer gradient favoring higher drug exposure. The result undermines the foundational assumption that greater amyloid clearance translates linearly to greater clinical benefit, a premise that has driven billions of dollars in R&D investment across the industry.

Despite the ambiguity, Biogen stated it would advance the candidate into late-stage development, signaling the company's conviction that a sufficient efficacy signal exists to justify the substantial investment required for pivotal trials. The decision carries significant financial and strategic risk. Late-stage Alzheimer's trials are among the most expensive in the pharmaceutical industry, often exceeding $1 billion in total costs and requiring thousands of patients followed over 18 months or longer. Committing to that spend on the back of a dose-response curve that doesn't behave as expected is a gamble — one that Biogen's leadership evidently believes is worth taking, given the near-term growth narrative tied to its co-developed antibody lecanemab (Leqembi).

Leqembi, which Biogen co-develops and co-commercializes with Eisai, received FDA accelerated approval in January 2023 and traditional approval in July 2023. The drug has been the cornerstone of Biogen's attempt to offset revenue declines from its multiple sclerosis franchise. Yet its commercial uptake has been slower than projected, constrained by safety concerns (notably amyloid-related imaging abnormalities, or ARIAs), the complexity of IV infusion logistics, and payer hesitancy. The latest mid-stage data adds another layer of uncertainty to Biogen's Alzheimer's thesis — and by extension, to the broader commercial case for anti-amyloid therapies.

For context, the FDA's own advisory committee process for lecanemab was contentious. Three members of the key FDA advisory panel resigned following the agency's controversial decision to grant approval, underscoring the deep divisions within the clinical and regulatory community about the strength of the evidence supporting anti-amyloid antibodies for Alzheimer's disease.

Why Did Biogen's Chief Medical Officer Resign — and What Does It Mean?

Endpoints News reported that Maha Makary, Biogen's Chief Medical Officer, resigned from her role. The departure strips the company of senior clinical leadership at precisely the moment when that leadership is most needed. Makary oversaw clinical development across Biogen's pipeline, including the Alzheimer's programs now entering their most consequential phase. Her resignation comes alongside the mid-stage data readout, compounding the sense of instability within Biogen's executive ranks.

Executive departures at this level are rarely isolated events. They often signal internal disagreements about pipeline prioritization, resource allocation, or the company's strategic direction. For BD teams evaluating a potential partnership or acquisition involving Biogen, the CMO vacancy raises immediate due diligence questions: Who will lead the late-stage development strategy for the new Alzheimer's candidate? How will the leadership gap affect regulatory interactions with the FDA and EMA? And does the departure reflect a broader loss of confidence in the anti-amyloid approach within Biogen's own ranks?

Biogen has not publicly detailed the reasons for Makary's departure, but the timing — juxtaposed with ambiguous clinical data and a high-stakes pipeline decision — will fuel speculation. For investors and potential partners, the key variable is whether Biogen can recruit a successor with sufficient Alzheimer's expertise and regulatory credibility to steer the program through pivotal trials and potential global filings.

How Are the FDA and EMA Diverging on Alzheimer's Regulation?

The regulatory environment for Alzheimer's treatments is anything but uniform. The FDA granted traditional approval to lecanemab in 2023, making it the first anti-amyloid antibody to receive full regulatory endorsement in the United States. The agency's decision was based on Phase III data showing a statistically significant 27% slowing of cognitive decline on the CDR-SB scale compared with placebo over 18 months — a modest but clinically meaningful effect in a disease with no disease-modifying alternatives.

Across the Atlantic, the European Medicines Agency has taken a more cautious posture. The EMA's Committee for Medicinal Products for Human Use (CHMP) has been reviewing the Marketing Authorization Application for lecanemab, and Biogen issued an update on April 1, 2025, acknowledging that the review process is ongoing. The EMA has historically applied a more stringent benefit-risk framework to Alzheimer's therapies, weighing the modest clinical benefits against the real risks of brain swelling and microhemorrhages associated with anti-amyloid antibodies.

This transatlantic divergence has direct consequences for BD teams. A drug approved in the US but delayed or restricted in Europe faces a significantly different revenue trajectory than one with synchronized global approval. License agreements, co-development deals, and M&A valuations for Alzheimer's assets must now account for the possibility of a fragmented regulatory outcome — with US access granted on one timeline and EU access on another, potentially with different label restrictions.

BD professionals should monitor the EMA's European Public Assessment Report (EPAR) for lecanemab for updates on the CHMP's deliberations. The FDA's drug approval page for lecanemab provides the full regulatory history, including advisory committee transcripts and approval letters. For clinical trial details, ClinicalTrials.gov entry NCT03887455 documents the pivotal Phase III trial design and results that underpinned the FDA's decision.

How Should Pharma BD Teams Recalibrate Their Alzheimer's Strategy?

Biogen's current situation creates both risk and opportunity for pharmaceutical business development. On the risk side, the inverted dose-response data introduces a new variable into asset valuation models. If the anti-amyloid mechanism produces unpredictable dose-response relationships, then Phase II readouts — already noisy in Alzheimer's — become even harder to interpret. BD teams will need to apply wider confidence intervals when modeling peak sales projections for amyloid-targeting candidates, and they should stress-test deal terms against scenarios where pivotal trials fail to replicate mid-stage signals.

On the opportunity side, smaller biotechs with early-stage Alzheimer's assets may find themselves under pressure to secure licensing deals or strategic partnerships. Companies with Phase II data that shows any signal of cognitive benefit — even an ambiguous one — could become acquisition targets for larger pharma companies seeking to build or replenish their neuroscience pipelines. The key is distinguishing between assets with genuine biological differentiation and those riding the coattails of the anti-amyloid hypothesis without a clear mechanistic rationale.

BD teams should also consider the competitive dynamics among the remaining players in the Alzheimer's space. Eli Lilly's donanemab, which received FDA approval in 2024, offers a direct comparator to lecanemab and has shown a somewhat more favorable safety profile in head-to-head analyses. Roche's gantenerumab program, by contrast, was discontinued after failing in Phase III — a reminder that the anti-amyloid approach is far from a guaranteed success. The competitive set is narrowing, and each data readout reshuffles the rankings.

From an investment perspective, Biogen's leadership vacuum and clinical ambiguity increase the company's risk premium. Investors will demand a higher return threshold for capital allocated to Biogen's Alzheimer's programs, which could depress the company's valuation and make it a more attractive take-private or partnership candidate — or, conversely, a riskier one, depending on the buyer's risk appetite. The next 12 to 18 months will be decisive: Biogen needs to demonstrate that its late-stage candidate can deliver clean, interpretable pivotal data, and it needs to fill the CMO role with a leader who can credibly represent the program before regulators and investors alike.

Frequently Asked Questions

Conclusion: Navigating the Alzheimer's Frontier

Biogen's latest chapter in the Alzheimer's saga underscores a truth that BD teams and investors have long understood but rarely confronted so directly: the anti-amyloid hypothesis remains scientifically plausible but commercially precarious. The inverted dose-response data, the CMO departure, and the transatlantic regulatory gap collectively raise the stakes for every company operating in this space. For dealmakers, the imperative is clear — build flexibility into deal structures, diversify pipeline exposure beyond single-mechanism approaches, and maintain disciplined valuation frameworks that account for the full spectrum of clinical and regulatory outcomes. The Alzheimer's market will eventually be enormous for the companies that get it right. The question is which companies those will be, and whether Biogen's current turbulence is a warning sign or a buying opportunity.

Related profiles

• Biogen

Related coverage

• Biogen and Eisai expand Leqembi access with subcutaneous maintenance dosing
• Eli Lilly Retatrutide Phase 3: Safety Data and Competitive Implications
• FDA Flavored Vape Ban: Youth Risk and Pharma Implications